Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Lansdale, PA, USA.
Genentech/Roche, South San Francisco, CA, USA;
PDA J Pharm Sci Technol. 2020 Mar-Apr;74(2):286-288. doi: 10.5731/pdajpst.2019.011239. Epub 2020 Mar 16.
It is important to identify, assess, and address current barriers to implementation of post-approval changes that are intended to ensure continued (uninterrupted) operations and drive innovation and continual improvement in a maximally efficient, agile, and flexible pharmaceutical manufacturing sector. Leveraging the International Conference for Harmonisation Quality Guideline Q10 provides regulatory relief when it comes to addressing changes related to excipients, specifically excipient supplier's name and address changes, which will ensure a sustainable, reliable global supply and the availability of high quality product to patients through the entire commercial lifecycle of a product without extensive regulatory oversight.
确定、评估和解决旨在确保持续(不间断)运营、推动创新和持续改进的药品制造行业的高效、灵活和敏捷性的批准后变更实施的当前障碍非常重要。利用国际协调会议质量指南 Q10,在解决与赋形剂相关的变更时,可以提供监管缓解,特别是赋形剂供应商名称和地址变更,这将确保通过产品整个商业生命周期的可持续、可靠的全球供应和高质量产品的可及性,而无需广泛的监管监督。